{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T01:02:38Z","timestamp":1784422958191,"version":"3.55.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40263-026-01281-0","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T05:13:08Z","timestamp":1772514788000},"page":"603-622","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9648-8973","authenticated-orcid":false,"given":"Wolfgang","family":"L\u00f6scher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9430-6806","authenticated-orcid":false,"given":"Chris","family":"Rundfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5950-2692","authenticated-orcid":false,"given":"Eugen","family":"Trinka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4277-8000","authenticated-orcid":false,"given":"Matthias","family":"Koepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7244-3722","authenticated-orcid":false,"given":"Pavel","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"issue":"3","key":"1281_CR1","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1021\/jm030913e","volume":"47","author":"BM Kenda","year":"2004","unstructured":"Kenda BM, Matagne AC, Talaga PE, Pasau PM, Differding E, Lallemand BI, et al. Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J Med Chem. 2004;47(3):530\u201349.","journal-title":"J Med Chem"},{"key":"1281_CR2","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/epi.13340","volume":"57","author":"H Klitgaard","year":"2016","unstructured":"Klitgaard H, Matagne A, Nicolas JM, Gillard M, Lamberty Y, De Ryck M, et al. Brivaracetam: rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. Epilepsia. 2016;57:538\u201348.","journal-title":"Epilepsia"},{"key":"1281_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/B978-1-4160-6171-7.00003-0","volume-title":"The epilepsies 3","author":"H Klitgaard","year":"2009","unstructured":"Klitgaard H, Matagne A. Mechanisms of action of levetiracetam and newer SV2A ligands. In: Shorvon S, Pedley TA, editors. The epilepsies 3. Amsterdam: Elsevier; 2009. p. 27\u201338."},{"issue":"1","key":"1281_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.nurt.2006.11.014","volume":"4","author":"B Bennett","year":"2007","unstructured":"Bennett B, Matagne A, Michel P, Leonard M, Cornet M, Meeus MA, et al. Seletracetam (UCB 44212). Neurotherapeutics. 2007;4(1):117\u201322.","journal-title":"Neurotherapeutics"},{"issue":"11","key":"1281_CR5","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s40263-016-0384-x","volume":"30","author":"W L\u00f6scher","year":"2016","unstructured":"L\u00f6scher W, Gillard M, Sands ZA, Kaminski RM, Klitgaard H. Synaptic vesicle glycoprotein 2A ligands in the treatment of epilepsy and beyond. CNS Drugs. 2016;30(11):1055\u201377.","journal-title":"CNS Drugs"},{"key":"1281_CR6","first-page":"1","volume":"10","author":"P Klein","year":"2018","unstructured":"Klein P, Diaz A, Gasalla T, Whitesides J. A review of the pharmacology and clinical efficacy of brivaracetam. Clin Pharmacol. 2018;10:1\u201322.","journal-title":"Clin Pharmacol"},{"key":"1281_CR7","unstructured":"Rundfeldt C, Klein P. Formulations comprising seletracetam and methods of use. WO 2025\/212556 A1, 09 October 2025 2025."},{"issue":"6","key":"1281_CR8","doi-asserted-by":"publisher","first-page":"566","DOI":"10.2174\/156720112803529828","volume":"9","author":"S Gizurarson","year":"2012","unstructured":"Gizurarson S. Anatomical and histological factors affecting intranasal drug and vaccine delivery. Curr Drug Deliv. 2012;9(6):566\u201382.","journal-title":"Curr Drug Deliv"},{"issue":"2","key":"1281_CR9","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.nurt.2009.01.002","volume":"6","author":"DP Wermeling","year":"2009","unstructured":"Wermeling DP. Intranasal delivery of antiepileptic medications for treatment of seizures. Neurotherapeutics. 2009;6(2):352\u20138.","journal-title":"Neurotherapeutics"},{"key":"1281_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.yebeh.2016.07.018","volume":"63","author":"SR Haut","year":"2016","unstructured":"Haut SR, Seinfeld S, Pellock J. Benzodiazepine use in seizure emergencies: a systematic review. Epilepsy Behav. 2016;63:109\u201317.","journal-title":"Epilepsy Behav"},{"key":"1281_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107391","volume":"112","author":"B Gidal","year":"2020","unstructured":"Gidal B, Klein P, Hirsch LJ. Seizure clusters, rescue treatments, seizure action plans: unmet needs and emerging formulations. Epilepsy Behav. 2020;112:107391.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"1281_CR12","first-page":"101","volume":"9","author":"JR Pollard","year":"2008","unstructured":"Pollard JR. Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy. Curr Opin Investig Drugs. 2008;9(1):101\u20137.","journal-title":"Curr Opin Investig Drugs"},{"key":"1281_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/ana.78128","author":"M Koepp","year":"2025","unstructured":"Koepp M, Poppert K-N, Felder T, Thomschewski A, Lafenthaler S, Klein P, et al. Intranasal seletracetam in a patient with reading epilepsy: first-in-human use to prevent reflex seizures. Ann Neurol. 2025. https:\/\/doi.org\/10.1002\/ana.78128.","journal-title":"Ann Neurol"},{"issue":"11","key":"1281_CR14","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1517\/17460441.2.11.1537","volume":"2","author":"H Klitgaard","year":"2007","unstructured":"Klitgaard H, Verdru P. Levetiracetam: the first SV2A ligand for the treatment of epilepsy. Expert Opin Drug Discov. 2007;2(11):1537\u201345.","journal-title":"Expert Opin Drug Discov"},{"key":"1281_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2025.108808","volume":"268","author":"M Bialer","year":"2025","unstructured":"Bialer M, Perucca E. From barbiturates to ganaxolone: the importance of chirality in drug development and in understanding the actions of old and new antiseizure medications. Pharmacol Ther. 2025;268:108808.","journal-title":"Pharmacol Ther"},{"key":"1281_CR16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0014-2999(95)00436-O","volume":"286","author":"M Noyer","year":"1995","unstructured":"Noyer M, Gillard M, Matagne A, H\u00e9nichart J-P, W\u00fclfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol. 1995;286:137\u201346.","journal-title":"Eur J Pharmacol"},{"key":"1281_CR17","doi-asserted-by":"publisher","first-page":"9861","DOI":"10.1073\/pnas.0308208101","volume":"101","author":"BA Lynch","year":"2004","unstructured":"Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA. 2004;101:9861\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"1281_CR18","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1038\/s41594-024-01430-3","volume":"31","author":"MM Bradberry","year":"2024","unstructured":"Bradberry MM, Chapman ER. Structural insights into SV2A and the mechanism of racetam anticonvulsants. Nat Struct Mol Biol. 2024;31(12):1818\u201320.","journal-title":"Nat Struct Mol Biol"},{"key":"1281_CR19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3389\/fncel.2015.00125","volume":"9","author":"J Correa-Basurto","year":"2015","unstructured":"Correa-Basurto J, Cuevas-Hernandez RI, Phillips-Farfan BV, Martinez-Archundia M, Romo-Mancillas A, Ramirez-Salinas GL, et al. Identification of the antiepileptic racetam binding site in the synaptic vesicle protein 2A by molecular dynamics and docking simulations. Front Cell Neurosci. 2015;9:125.","journal-title":"Front Cell Neurosci"},{"issue":"2","key":"1281_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/epi.13638","volume":"58","author":"MD Wood","year":"2017","unstructured":"Wood MD, Gillard M. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein. Epilepsia. 2017;58(2):255\u201362.","journal-title":"Epilepsia"},{"issue":"9","key":"1281_CR21","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1111\/epi.14532","volume":"59","author":"MD Wood","year":"2018","unstructured":"Wood MD, Sands ZA, Vandenplas C, Gillard M. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein. Epilepsia. 2018;59(9):e147\u201351.","journal-title":"Epilepsia"},{"issue":"4","key":"1281_CR22","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/j.1528-1167.2008.01915.x","volume":"50","author":"G Martella","year":"2009","unstructured":"Martella G, Bonsi P, Sciamanna G, Platania P, Madeo G, Tassone A, et al. Seletracetam (ucb 44212) inhibits high-voltage-activated Ca2+ currents and intracellular Ca2+ increase in rat cortical neurons in vitro. Epilepsia. 2009;50(4):702\u201310.","journal-title":"Epilepsia"},{"key":"1281_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.107966","volume":"168","author":"GJ Sills","year":"2020","unstructured":"Sills GJ, Rogawski MA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 2020;168:107966.","journal-title":"Neuropharmacology"},{"issue":"1","key":"1281_CR24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.eplepsyres.2009.09.024","volume":"88","author":"C Zona","year":"2010","unstructured":"Zona C, Pieri M, Carunchio I, Curcio L, Klitgaard H, Margineanu DG. Brivaracetam (ucb 34714) inhibits Na(+) current in rat cortical neurons in culture. Epilepsy Res. 2010;88(1):46\u201354.","journal-title":"Epilepsy Res"},{"issue":"5","key":"1281_CR25","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/sj.bjp.0704766","volume":"136","author":"JM Rigo","year":"2002","unstructured":"Rigo JM, Hans G, Nguyen L, Rocher V, Belachew S, Malgrange B, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal. Br J Pharmacol. 2002;136(5):659\u201372.","journal-title":"Br J Pharmacol"},{"issue":"5247","key":"1281_CR26","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1126\/science.271.5247.369","volume":"271","author":"EH Buhl","year":"1996","unstructured":"Buhl EH, Otis TS, Mody I. Zinc-induced collapse of augmented inhibition by GABA in a temporal lobe epilepsy model. Science. 1996;271(5247):369\u201373.","journal-title":"Science"},{"issue":"Suppl 6","key":"1281_CR27","first-page":"S96","volume":"41","author":"DA Coulter","year":"2000","unstructured":"Coulter DA. Mossy fiber zinc and temporal lobe epilepsy: pathological association with altered \u201cepileptic\u201d gamma-aminobutyric acid A receptors in dentate granule cells. Epilepsia. 2000;41(Suppl 6):S96\u20139.","journal-title":"Epilepsia"},{"key":"1281_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/bs.vh.2017.12.001","volume":"107","author":"DS Reddy","year":"2018","unstructured":"Reddy DS. GABA-A receptors mediate tonic inhibition and neurosteroid sensitivity in the brain. Vitam Horm. 2018;107:177\u201391.","journal-title":"Vitam Horm"},{"key":"1281_CR29","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.pharmthera.2018.08.013","volume":"193","author":"U Doboszewska","year":"2019","unstructured":"Doboszewska U, M\u00c5\u201ayniec K, Wla\u00c5\u00ba A, Poleszak E, Nowak G, Wla\u00c5\u00ba P. Zinc signaling and epilepsy. Pharmacol Ther. 2019;193:156\u201377.","journal-title":"Pharmacol Ther"},{"key":"1281_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2025.101360","volume":"103","author":"N Mizzi","year":"2025","unstructured":"Mizzi N, Blundell R. Glycine receptors: structure, function, and therapeutic implications. Mol Aspects Med. 2025;103:101360.","journal-title":"Mol Aspects Med"},{"issue":"4","key":"1281_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.70061","volume":"169","author":"SD Fraser","year":"2025","unstructured":"Fraser SD, Klaassen RV, Villmann C, Smit AB, Harvey RJ. Milestone review: unlocking the proteomics of glycine receptor complexes. J Neurochem. 2025;169(4):e70061.","journal-title":"J Neurochem"},{"key":"1281_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114786","volume":"193","author":"JL Green","year":"2021","unstructured":"Green JL, dos Santos WF, Fontana ACK. Role of glutamate excitotoxicity and glutamate transporter EAAT2 in epilepsy: opportunities for novel therapeutics development. Biochem Pharmacol. 2021;193:114786.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"1281_CR33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11064-025-04400-3","volume":"50","author":"G Zhang","year":"2025","unstructured":"Zhang G, Huang S, Wei M, Wu Y, Wang J. Excitatory amino acid transporters as therapeutic targets in the treatment of neurological disorders: their roles and therapeutic prospects. Neurochem Res. 2025;50(3):155.","journal-title":"Neurochem Res"},{"issue":"7021","key":"1281_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nature03180","volume":"433","author":"JD Rothstein","year":"2005","unstructured":"Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005;433(7021):73\u20137.","journal-title":"Nature"},{"issue":"1","key":"1281_CR35","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20180992","volume":"217","author":"XX Liu","year":"2020","unstructured":"Liu XX, Yang L, Shao LX, He Y, Wu G, Bao YH, et al. Endothelial Cdk5 deficit leads to the development of spontaneous epilepsy through CXCL1\/CXCR2-mediated reactive astrogliosis. J Exp Med. 2020;217(1):e20180992.","journal-title":"J Exp Med"},{"issue":"16","key":"1281_CR36","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1089\/neu.2012.2712","volume":"30","author":"GS Goodrich","year":"2013","unstructured":"Goodrich GS, Kabakov AY, Hameed MQ, Dhamne SC, Rosenberg PA, Rotenberg A. Ceftriaxone treatment after traumatic brain injury restores expression of the glutamate transporter, GLT-1, reduces regional gliosis, and reduces post-traumatic seizures in the rat. J Neurotrauma. 2013;30(16):1434\u201341.","journal-title":"J Neurotrauma"},{"issue":"9","key":"1281_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/cells12091233","volume":"12","author":"W L\u00f6scher","year":"2023","unstructured":"L\u00f6scher W, White HS. Animal models of drug-resistant epilepsy as tools for deciphering the cellular and molecular mechanisms of pharmacoresistance and discovering more effective treatments. Cells. 2023;12(9):1233.","journal-title":"Cells"},{"issue":"1\u20133","key":"1281_CR38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejphar.2009.04.024","volume":"614","author":"A Matagne","year":"2009","unstructured":"Matagne A, Margineanu DG, Potschka H, L\u00f6scher W, Michel P, Kenda B, et al. Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy. Eur J Pharmacol. 2009;614(1\u20133):30\u20137.","journal-title":"Eur J Pharmacol"},{"key":"1281_CR39","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s40263-021-00827-8","volume":"35","author":"W L\u00f6scher","year":"2021","unstructured":"L\u00f6scher W, Klein P. The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond. CNS Drugs. 2021;35:935\u201363.","journal-title":"CNS Drugs"},{"key":"1281_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107811","volume":"166","author":"KS Wilcox","year":"2020","unstructured":"Wilcox KS, West PJ, Metcalf CS. The current approach of the Epilepsy Therapy Screening Program Contract Site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy. Neuropharmacology. 2020;166:107811.","journal-title":"Neuropharmacology"},{"key":"1281_CR41","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/jps.3030460322","volume":"46","author":"NW Dunham","year":"1957","unstructured":"Dunham NW, Miya TS. A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc. 1957;46:208\u20139.","journal-title":"J Am Pharm Assoc"},{"key":"1281_CR42","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.eplepsyres.2016.05.016","volume":"126","author":"W L\u00f6scher","year":"2016","unstructured":"L\u00f6scher W. Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies. Epilepsy Res. 2016;126:157\u201384.","journal-title":"Epilepsy Res"},{"issue":"1","key":"1281_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eplepsyres.2006.10.008","volume":"73","author":"M Bialer","year":"2007","unstructured":"Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res. 2007;73(1):1\u201352.","journal-title":"Epilepsy Res"},{"key":"1281_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.110241","volume":"164","author":"D Kasteleijn-Nolst Trenit\u00e9","year":"2025","unstructured":"Kasteleijn-Nolst Trenit\u00e9 D, Stockis A, Hirsch E, Genton P, Abou-Khalil BW, French JA, et al. A multicenter phase II randomized, placebo-controlled single-blind trial with the SV2A ligand seletracetam in photosensitive epilepsy patients. Epilepsy Behav. 2025;164:110241.","journal-title":"Epilepsy Behav"},{"key":"1281_CR45","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1111\/epi.18444","volume":"66","author":"W L\u00f6scher","year":"2025","unstructured":"L\u00f6scher W, Kasteleijn-Nolst Trenit\u00e9 D. The human photosensitive epilepsy model for clinical proof-of-principle trials of novel antiseizure medications. 2. Analysis of drug trials and predictive values of the model. Epilepsia. 2025;66:2619\u201338.","journal-title":"Epilepsia"},{"key":"1281_CR46","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1111\/epi.18420","volume":"66","author":"W L\u00f6scher","year":"2025","unstructured":"L\u00f6scher W, Stockis A, Klein P, Kasteleijn-Nolst Trenit\u00e9 D. Pharmacodynamic interactions between seletracetam and antiseizure comedications in the human photosensitivity model. Epilepsia. 2025;66:e106\u201313.","journal-title":"Epilepsia"},{"issue":"6","key":"1281_CR47","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1111\/epi.18338","volume":"66","author":"S Beniczky","year":"2025","unstructured":"Beniczky S, Trinka E, Wirrell E, Abdulla F, Al Baradie R, Alonso VM, et al. Updated classification of epileptic seizures: position paper of the International League Against Epilepsy. Epilepsia. 2025;66(6):1804\u201323.","journal-title":"Epilepsia"},{"key":"1281_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106748","volume":"177","author":"S Chung","year":"2021","unstructured":"Chung S, Szaflarski JP, Choi EJ, Wilson JC, Kharawala S, Kaur G, et al. A systematic review of seizure clusters: prevalence, risk factors, burden of disease and treatment patterns. Epilepsy Res. 2021;177:106748.","journal-title":"Epilepsy Res"},{"issue":"1","key":"1281_CR49","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/21556660.2021.1962671","volume":"10","author":"B Mesraoua","year":"2021","unstructured":"Mesraoua B, Abou-Khalil B, Hosni KR, Melikyan G, Al Hail H, Asadi-Pooya AA. Seizure clusters. J Drug Assess. 2021;10(1):86\u201390.","journal-title":"J Drug Assess"},{"issue":"4","key":"1281_CR50","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/epd2.20243","volume":"26","author":"JE Pina-Garza","year":"2024","unstructured":"Pina-Garza JE, Chez M, Cloyd J, Hirsch LJ, K\u00e4lvi\u00e4inen R, Klein P, et al. Outpatient management of prolonged seizures and seizure clusters to prevent progression to a higher-level emergency: consensus recommendations of an expert working group. Epilept Disord. 2024;26(4):484\u201397.","journal-title":"Epilept Disord"},{"issue":"Suppl 1","key":"1281_CR51","first-page":"S74","volume":"37","author":"WG Mitchell","year":"1996","unstructured":"Mitchell WG. Status epilepticus and acute repetitive seizures in children, adolescents, and young adults: etiology, outcome, and treatment. Epilepsia. 1996;37(Suppl 1):S74\u201380.","journal-title":"Epilepsia"},{"key":"1281_CR52","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.yebeh.2018.09.035","volume":"88","author":"K Detyniecki","year":"2018","unstructured":"Detyniecki K, O\u2019Bryan J, Choezom T, Rak G, Ma C, Zhang S, et al. Prevalence and predictors of seizure clusters: a prospective observational study of adult patients with epilepsy. Epilepsy Behav. 2018;88:349\u201356.","journal-title":"Epilepsy Behav"},{"issue":"13","key":"1281_CR53","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s40265-015-0454-2","volume":"75","author":"E Trinka","year":"2015","unstructured":"Trinka E, H\u00f6fler J, Leitinger M, Brigo F. Pharmacotherapy for status epilepticus. Drugs. 2015;75(13):1499\u2013521.","journal-title":"Drugs"},{"issue":"2","key":"1281_CR54","first-page":"559","volume":"28","author":"E Trinka","year":"2022","unstructured":"Trinka E, Leitinger M. Management of status epilepticus, refractory status epilepticus, and super-refractory status epilepticus. Continuum (Minneap Minn ). 2022;28(2):559\u2013602.","journal-title":"Continuum (Minneap Minn )"},{"key":"1281_CR55","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/epi4.70054","volume":"10","author":"M Chez","year":"2025","unstructured":"Chez M, Klein P, Becker D, Peters JM, Carrazana E, Rabinowicz AL. Exploring proposed recommendations for immediate-use seizure medication: treating both cluster and prolonged seizures with diazepam nasal spray. Epilepsia Open. 2025;10:999\u20131008.","journal-title":"Epilepsia Open"},{"issue":"9","key":"1281_CR56","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40263-015-0271-x","volume":"29","author":"F Brigo","year":"2015","unstructured":"Brigo F, Nardone R, Tezzon F, Trinka E. A common reference-based indirect comparison meta-analysis of buccal versus intranasal midazolam for early status epilepticus. CNS Drugs. 2015;29(9):741\u201357.","journal-title":"CNS Drugs"},{"key":"1281_CR57","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.yebeh.2015.02.030","volume":"49","author":"F Brigo","year":"2015","unstructured":"Brigo F, Nardone R, Tezzon F, Trinka E. Nonintravenous midazolam versus intravenous or rectal diazepam for the treatment of early status epilepticus: a systematic review with meta-analysis. Epilepsy Behav. 2015;49:325\u201336.","journal-title":"Epilepsy Behav"},{"key":"1281_CR58","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.yebeh.2015.04.027","volume":"49","author":"R K\u00e4lvi\u00e4inen","year":"2015","unstructured":"K\u00e4lvi\u00e4inen R. Intranasal therapies for acute seizures. Epilepsy Behav. 2015;49:303\u20136.","journal-title":"Epilepsy Behav"},{"issue":"4","key":"1281_CR59","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/JNN.0000000000000769","volume":"56","author":"PO Shafer","year":"2024","unstructured":"Shafer PO, Dean P, Brooks L, Gidal B, Misra SN, Carrazana E. Intranasal delivery of medications for the treatment of neurologic conditions: a pharmacology update. J Neurosci Nurs. 2024;56(4):136\u201342.","journal-title":"J Neurosci Nurs"},{"key":"1281_CR60","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jconrel.2016.07.001","volume":"237","author":"M Kapoor","year":"2016","unstructured":"Kapoor M, Cloyd JC, Siegel RA. A review of intranasal formulations for the treatment of seizure emergencies. J Control Rel. 2016;237:147\u201359.","journal-title":"J Control Rel"},{"issue":"6","key":"1281_CR61","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/jps.20318","volume":"94","author":"CL Graff","year":"2005","unstructured":"Graff CL, Pollack GM. Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci. 2005;94(6):1187\u201395.","journal-title":"J Pharm Sci"},{"issue":"7","key":"1281_CR62","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","volume":"64","author":"JJ Lochhead","year":"2012","unstructured":"Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012;64(7):614\u201328.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"1281_CR63","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s13311-020-00985-5","volume":"18","author":"D Zolkowska","year":"2021","unstructured":"Zolkowska D, Wu CY, Rogawski MA. Intranasal allopregnanolone confers rapid seizure protection: evidence for direct nose-to-brain delivery. Neurotherapeutics. 2021;18(1):544\u201355.","journal-title":"Neurotherapeutics"},{"issue":"3","key":"1281_CR64","doi-asserted-by":"publisher","first-page":"120","DOI":"10.9740\/mhc.2016.05.120","volume":"6","author":"A Schmitz","year":"2016","unstructured":"Schmitz A. Benzodiazepine use, misuse, and abuse: a review. Ment Health Clin. 2016;6(3):120\u20136.","journal-title":"Ment Health Clin"},{"issue":"3","key":"1281_CR65","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1212\/WNL.0b013e31825fdf3a","volume":"79","author":"AE Vaudano","year":"2012","unstructured":"Vaudano AE, Carmichael DW, Salek-Haddadi A, Rampp S, Stefan H, Lemieux L, et al. Networks involved in seizure initiation. A reading epilepsy case studied with EEG-fMRI and MEG. Neurology. 2012;79(3):249\u201353.","journal-title":"Neurology"},{"key":"1281_CR66","doi-asserted-by":"publisher","first-page":"140","DOI":"10.47583\/ijpsrr.2020.v65i02.022","volume":"65","author":"SA Chore","year":"2020","unstructured":"Chore SA, Dighade SJ. Review on buccal drug delivery system. Int J Pharm Sci Rev Res. 2020;65:140\u20138.","journal-title":"Int J Pharm Sci Rev Res"},{"issue":"9153","key":"1281_CR67","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S0140-6736(98)06425-3","volume":"353","author":"RC Scott","year":"1999","unstructured":"Scott RC, Besag FM, Neville BG. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet. 1999;353(9153):623\u20136.","journal-title":"Lancet"},{"key":"1281_CR68","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.pediatrneurol.2024.06.014","volume":"158","author":"MZ Mohammed","year":"2024","unstructured":"Mohammed MZ, Elagouza I, El Gaafary M, El Garhy R, El Rashidy O. Intranasal versus buccal versus intramuscular midazolam for the home and emergency treatment of acute seizures in pediatric patients: a randomized controlled trial. Pediatr Neurol. 2024;158:135\u201343.","journal-title":"Pediatr Neurol"},{"issue":"9","key":"1281_CR69","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.1021\/acschemneuro.9b00351","volume":"10","author":"KA Stout","year":"2019","unstructured":"Stout KA, Dunn AR, Hoffman C, Miller GW. The synaptic vesicle glycoprotein 2: structure, function, and disease relevance. ACS Chem Neurosci. 2019;10(9):3927\u201338.","journal-title":"ACS Chem Neurosci"},{"key":"1281_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.864514","volume":"16","author":"R Rossi","year":"2022","unstructured":"Rossi R, Arjmand S, B\u00c3\u00a6rentzen SL, Gjedde A, Landau AM. Synaptic vesicle glycoprotein 2A: features and functions. Front Neurosci. 2022;16:864514.","journal-title":"Front Neurosci"},{"issue":"1","key":"1281_CR71","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.16308","volume":"169","author":"JA Hogg","year":"2025","unstructured":"Hogg JA, Cousin MA. Control of synaptotagmin-1 trafficking by SV2A-mechanism and consequences for presynaptic function and dysfunction. J Neurochem. 2025;169(1):e16308.","journal-title":"J Neurochem"},{"issue":"1\u20133","key":"1281_CR72","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejphar.2011.04.064","volume":"664","author":"M Gillard","year":"2011","unstructured":"Gillard M, Fuks B, Leclercq K, Matagne A. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol. 2011;664(1\u20133):36\u201344.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"1281_CR73","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.nucmedbio.2016.03.004","volume":"43","author":"S Estrada","year":"2016","unstructured":"Estrada S, Lubberink M, Thibblin A, Sprycha M, Buchanan T, Mestdagh N, et al. [(11)C]UCB-A, a novel PET tracer for synaptic vesicle protein 2A. Nucl Med Biol. 2016;43(6):325\u201332.","journal-title":"Nucl Med Biol"},{"key":"1281_CR74","unstructured":"Leese PT, Goldwater DR, Hulhoven R, Salas E, Toublanc N, Chen D et al. Seletracetam (UCB 44212): single and multiple rising dose safety, tolerability and pharmacokinetics in healthy subjects. AES Abstracts 2006; Abstract number 2.131."},{"key":"1281_CR75","unstructured":"Kasteleijn-Nolst Trenit\u00e9 D, Abou-Khalil B, French J, Genton P, Hirsch E, Masnou P et al. Proof of principle of the new AED seletracetam (UCB 44212) in the photosensitivity model. AES Abstracts 2006; Abstract number 2.123."}],"updated-by":[{"DOI":"10.1007\/s40263-026-01304-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000}}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01281-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01281-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01281-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T22:02:30Z","timestamp":1781820150000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01281-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1281"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01281-0","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Figure 1 has been updated in the original publication.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40263-026-01304-w","URL":"https:\/\/doi.org\/10.1007\/s40263-026-01304-w","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors are cofounders of PrevEp, Inc. (Bethesda, MD, USA). Wolfgang L\u00f6scher has received consulting fees (2020\u20132024) from Addex\/Neurosterix, Angelini Pharma, Atlas Venture, Axonis, Lundbeck, Axonis Therapeutics, Clexio Biosciences, Cogent Biosolutions, Ovid, Idorsia, ND Capital, Sintetica, SynapCell, and Selene Therapeutics, and has received research support from the German Research Foundation (Bonn, Germany). Pavel Klein has served as a consultant, advisory board member or speaker (2020\u20132024) for Abbott, Angelini Pharma, Aquestive, Arvelle Therapeutics, Aucta Pharmaceuticals, Dr Reddy's, Eisai, GRIN Therapeutics, Jazz Pharmaceuticals, Longboard Pharmaceuticals, Neurelis, Inc., Neurona, Paladin, SK Life Science, Sunovion, UCB Pharma, UNEEG, UniQure, and Xenon Pharma, is a member of the Medical Advisory Board of Stratus and of the Scientific Advisory Boards of OB Pharma and of NEUmirna, and has received research support from CURE\/Department of Defense and from the NIH\/SBIR. Eugen Trinka reports personal fees from EVER Pharma, Marinus, Arvelle, Angelini, Argenx, Alexion, Medtronic, BIAL, NewBridge, GL Pharma, GlaxoSmithKline, Boehringer Ingelheim, LivaNova, Lundbeck, Eisai, UCB, Biogen, Sanofi, Jazz Pharmaceuticals, STOKE Therapeutics, Rapport, and Actavis. He is co-director of the European Consortium on Epilepsy Trials (ECET). His institution received grants from Biogen, UCB Pharma, Eisai, Red Bull, Merck, Bayer, the European Union, FWF \u00d6sterreichischer Fond zur Wissenschaftsforderung, Bundesministerium f\u00fcr Wissenschaft und Forschung, and Jubil\u00e4umsfond der \u00d6sterreichischen Nationalbank. None related to the presented work. Eugen Trinka is an Editorial Board member of CNS Drugs. He was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Matthias Koepp or his department has received grants from Angelini, Biohavn, UCB, and Xenon, has received consulting fees from Angelini, Bial, Biocodex, Eisai, Jazz Pharma, LivaNova, Sanofi, and UCB Pharma, is co-founder of PrevEp, Inc., and has received research funding from the MRC, Wellcome Trust, Epilepsy Research UK, Epilepsy Society UK, UCLH Foundation Trust, and Henry Smith Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The datasets generated during and\/or analyzed during the current review are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Idea origination\u2014WL; outline creation\/revision\u2014WL, PK, and CR; literature search\/data analysis\u2014WL, PK, and CR; drafted manuscript\u2014WL, PK, and CR; critically revised manuscript\u2014WL, PK, CR, MK, and ET; all authors have read and approved the final submitted manuscript and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}